ATW SPAC Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

ATW SPAC Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-107,701	Closed	-$438K	–	178
2021 Q3	$438K	Hold	107,701	–	–	0.08%	125
2021 Q2	$523K	Buy	+107,701	New	+$48.5K	0.13%	106

Other funds holding RVPHW

BCM

BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

ATW SPAC Management's RVPHW Position: Q4 2021 in Review

ATW SPAC Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q4 2021, closing a stake of 107,701 shares — an estimated $438K sold.

ATW SPAC Management first reported a position in RVPHW in Q2 2021 and held it in 2 quarters. The position peaked at $523K in Q2 2021. 6 funds tracked by Wall St. Rank hold RVPHW as of Q4 2021.

ATW SPAC Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q4 2021 after selling out during the quarter.
ATW SPAC Management sold 107,701 Reviva Pharmaceuticals Warrants shares in Q4 2021, an estimated $438K.
ATW SPAC Management first reported a position in Reviva Pharmaceuticals Warrants in Q2 2021 and held it in 2 quarters.
ATW SPAC Management's Reviva Pharmaceuticals Warrants position peaked at $523K in Q2 2021.
6 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q4 2021.

Based on ATW SPAC Management's 13F filing for Q4 2021, filed 14 Feb 2022.